Thursday, January 7, 2016
RASRx Finds Funding For Muscular Dystrophy Treatment
RASRx, a biopharmaceuticals startup developing an oral therapy to treat muscle degeneration, has scored funding from venture philanthropy company CureDuchenne Ventures, CureDuchenne Ventures announced Tuesday. Size of the funding was not announced. CureDuchenne funds research into finding a cure for Duchenne muscular dystrophy, a genetic disease that causes muscles to degenerate. As part of the funding, Jak Knowles of CureDuchenne Ventures join's the RASRx board of directors. RASRx was founded by Kathleen Rodgers, and is based on research licensed from the University of Southern California.